Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide

Jacobs, Claudia; Kayser, Oliver; Müller, R.H.

doi:10.1016/s0378-5173(99)00412-3

Cited by 199 publications

(92 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…; greater than minimum inhibitory concentration, for most of the mycobacterium avium strains. Tarazepide is formulated as nanosuspension in order to overcome the use of surfactants and cyclodextrins to improve the bioavailability [14].…”

Section: Parenteral Drug Deliverymentioning

confidence: 99%

Nanosuspension: An Overview

Aher¹,

Malsane²,

Saudagar³

2017

Int J Curr Pharm Sci

View full text Add to dashboard Cite

Nanosuspensions are important carriers to develop novel drug formulations. Nanosuspensions have emerged as a promising strategy for the efficient delivery of hydrophobic drugs because of their versatile features and unique advantages. Nanosuspension technology solved the problem of drugs which are poorly aqueous soluble and less bioavailability. Stability and bioavailability of the drugs can be improved by the Nanosuspension technology. Techniques such as media milling and high-pressure homogenization have been used commercially for producing nanosuspensions. Nanosuspensions can be delivered by oral, parenteral, pulmonary and ocular routes. Nanosuspensions can also be used for targeted drug delivery when incorporated in theOcular inserts and mucoadhesive hydrogels. Currently, efforts are being directed to extending their applications in sitespecific drug delivery.

show abstract

Section: Parenteral Drug Deliverymentioning

confidence: 99%

Nanosuspension: An Overview

Aher¹,

Malsane²,

Saudagar³

2017

Int J Curr Pharm Sci

View full text Add to dashboard Cite

show abstract

“…Particle aggregation was likely to occur if particles possessed too low zeta potential to provide sufficient electric repulsion or steric repulsion between each other. In general, a zeta potential of at least −30 mV for electrostatically stabilized systems or −20 mV for sterically stabilized systems was desired to obtain a physically stable nanosuspension (Jacobs et al, 2000). Therefore, the zeta potential could predict the storage stability of nanosuspension.…”

Section: Characterization Of Cur-nsmentioning

confidence: 99%

“…In contrast, CUR-NS showed enhanced solubility (15.92 ± 3.35 μg/ml), which was nearly 2-fold that of the mixture of pristine CUR and excipients (7.80 ± 0.16 μg/ ml), and more than 600-fold that (lower than 25 ng/ ml) of pristine CUR. The increased solubility for nanosuspension could be explained by Ostwald-Freundlich's equation (Voorhees, 1985;Jacobs et al, 2000):…”

Section: Characterization Of Cur-nsmentioning

confidence: 99%

Preparation and characterization of intravenously injectable curcumin nanosuspension

Gao

Sun

et al. 2010

Drug Delivery

View full text Add to dashboard Cite

“…Drug nanosuspensions represent crystalline drug particles often stabilized by non-ionic PEGcontaining surfactants or with mixtures of lipids [203,204]. They can be manufactured by a variety of techniques such as media milling, high-pressure homogenization or using emulsions and microemulsions as templates [205,206].…”

Section: Nanoparticlesmentioning

confidence: 99%

Nanomedicine in the diagnosis and therapy of neurodegenerative disorders

Kabanov

Gendelman

2007

Progress in Polymer Science

234

138

View full text Add to dashboard Cite

Neurodegenerative and infectious disorders including Alzheimer's and Parkinson's diseases, amyotrophic lateral sclerosis, and stroke are rapidly increasing as population's age. Alzheimer's disease alone currently affects 4.5 million Americans, and more than $100 billion is spent per year on medical and institutional care for affected people. Such numbers will double in the ensuing decades. Currently disease diagnosis for all disorders is made, in large measure, on clinical grounds as laboratory and neuroimaging tests confirm what is seen by more routine examination. Achieving early diagnosis would enable improved disease outcomes. Drugs, vaccines or regenerative proteins present "real" possibilities for positively affecting disease outcomes, but are limited in that their entry into the brain is commonly restricted across the blood-brain barrier. This review highlights how these obstacles can be overcome by polymer science and nanotechnology. Such approaches may improve diagnostic and therapeutic outcomes. New developments in polymer science coupled with cell-based delivery strategies support the notion that diseases that now have limited therapeutic options can show improved outcomes by advances in nanomedicine.

show abstract

Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide

Cited by 199 publications

References 0 publications

Nanosuspension: An Overview

Nanosuspension: An Overview

Preparation and characterization of intravenously injectable curcumin nanosuspension

Nanomedicine in the diagnosis and therapy of neurodegenerative disorders

Contact Info

Product

Resources

About